<DOC>
	<DOC>NCT01361308</DOC>
	<brief_summary>The purpose of this study is to assess the safety &amp; efficacy of Brisdelle (paroxetine mesylate) Capsules 7.5 mg for treatment of vasomotor symptoms (VMS) associated with menopause.</brief_summary>
	<brief_title>Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)</brief_title>
	<detailed_description>This is 12-week, multicenter, double-blind, randomized, placebo-controlled study of Brisdelle (paroxetine mesylate) Capsules 7.5 mg and placebo capsules in subjects with moderate to severe postmenopausal VMS, defined as follows: - Moderate VMS: Sensation of heat with sweating, able to continue activity - Severe VMS: Sensation of heat with sweating, causing cessation of activity The study is comprised of a screening period, a run-in period, a baseline visit, and a double-blind treatment period.</detailed_description>
	<mesh_term>Paroxetine</mesh_term>
	<criteria>1. Female, ≥ 40 years of age at screening (inclusive) 2. Reported more than 78 moderate to severe hot flashes per day (average) or 5060 moderate to severe hot flashes per week for at least 30 days prior to the screening visit 3. Spontaneous amenorrhea for at least 12 consecutive months or 4. Amenorrhea for at least 6 months and meet the biochemical criteria for menopause or 5. Bilateral salpingooophorectomy ≥ 6 weeks with or without hysterectomy 1. Known nonresponder to previous Selective serotonin reuptake inhibitor (SSRI) or Serotonin norepinephrine reuptake inhibitor (SNRI) treatment for VMS 2. History of self injurious behavior 3. History of clinical diagnosis of depression or treatment for depression 4. History of clinical diagnosis of borderline personality disorder 5. Use of an investigational study medication within 30 days prior to screening or during the study 6. Concurrent participation in another clinical trial or previous participation in this trial 7. Family of investigationalsite staff</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Menopause</keyword>
	<keyword>Vasomotor Symptoms</keyword>
	<keyword>Hot Flashes Perimenopause</keyword>
	<keyword>Climacteric Symptoms</keyword>
	<keyword>Mesafem</keyword>
	<keyword>Low-Dose Mesylate salt of Paroxetine (LDMP)</keyword>
</DOC>